Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1108 Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
NCT07285265Phase 1Active, not recruiting
- Sponsor
- Abogen Bioscience
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABO1108 in herpes zoster (HZ) (3 cohorts), sponsored by Abogen Bioscience. Primary endpoints: Incidence of solicited adverse events and adverse reactions and Incidence of unsolicited adverse events and adverse reactions. Started May 2025; status: active, not recruiting.
02
Drugs
ABO1108
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07285265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285265.